Aldehyde Dehydrogenase Inhibitors: a Comprehensive Review of the Pharmacology, Mechanism of Action, Substrate Specificity, and Clinical Application

Vindhya Koppaka, David C. Thompson, Ying Chen, Manuel Ellermann, Kyriacos C. Nicolaou, Risto O. Juvonen, Dennis Petersen, Richard A. Deitrich, Thomas D. Hurley, and Vasilis Vasiliou

Abstract

Aldehyde dehydrogenases (ALDHs) belong to a superfamily of enzymes that play a key role in the metabolism of aldehydes of both endogenous and exogenous derivation. The human ALDH superfamily comprises 19 isozymes that possess important physiological and toxicological functions. The ALDH1A subfamily plays a pivotal role in embryogenesis and development by mediating retinoic acid signaling. ALDH2, as a key enzyme that oxidizes acetaldehyde, is crucial for alcohol metabolism. ALDH1A1 and ALDH3A1 are lens and corneal crystallins, which are essential elements of the cellular defense mechanism against ultraviolet radiation-induced damage in ocular tissues. Many ALDH isozymes are important in oxidizing reactive aldehydes derived from lipid peroxidation and thereby help maintain cellular homeo-
stasis. Increased expression and activity of ALDH isozymes have been reported in various human cancers and are associated with cancer relapse. As a direct consequence of their significant physiological and toxicological roles, inhibitors of the ALDH enzymes have been developed to treat human diseases. This review summarizes known ALDH inhibitors, their mechanisms of action, isozyme selectivity, potency, and clinical uses. The purpose of this review is to 1) establish the current status of pharmacological inhibition of the ALDHs, 2) provide a rationale for the continued development of ALDH isozyme-selective inhibitors, and 3) identify the challenges and potential therapeutic rewards associated with the creation of such agents.

I. Introduction

The aldehyde dehydrogenases (ALDHs) have a surprisingly broad spectrum of biological activities. ALDH activity is crucial to the biosynthesis of retinoic acid, an important regulator of vertebrate development, and to the metabolism of the neurotransmitter GABA (Yoshida et al., 1992; Vasiliiou et al., 2000; Sophos and Vasiliiou, 2003; Vasiliiou and Nebert, 2005; Marchitti et al., 2008; Niederreither and Dollè, 2008; Kim et al., 2011a). From the toxicological point of view, dehydrogenase enzymatic activity of ALDHs is important in alcohol metabolism through aldehyde detoxification and for cellular homeostasis by eliminating reactive aldehydes derived from lipid peroxidation (Vasiliiou et al., 2000). Increased ALDH activity, however, has been found to interfere with certain chemotherapeutic treatments (Sládek, 1999; Jelski et al., 2007; Tanei et al., 2009; Deng et al., 2010). In addition, ALDHs can act as esterases (Blackwell et al., 1983; Yoshida et al., 1998) and also perform nonenzymatic functions, such as reducing osmotic stress in plants, binding to macromolecules (such as androgen and cholesterol) and protecting the mammalian cornea from UV exposure (Estey et al., 2007; Chen et al., 2009).

Genetic polymorphisms of ALDH isozymes that result in diminished enzymatic activity are associated with several clinical disease states, including Sjögren-Larsson syndrome, Type 2 hyperprolinemia, pyridoxine-dependent seizures, hyperammonemia, γ-hydroxybutyric aciduria, and alcoholic liver disease (Marchitti et al., 2008).

In the past, the well established role of ALDH in alcohol metabolism has driven the research behind the discovery of ALDH inhibitors. Accumulation of acetaldehyde after ethanol consumption leads to the development of unpleasant physiological effects comprising facial flushing, nausea, and tachycardia. This condition, termed the alcohol flushing syndrome, commonly occurs in subjects possessing a genetic polymorphism that confers upon them reduced activity of ALDH2, the enzyme responsible for the efficient metabolism of acetaldehyde. This observation led to the initial development of selective ALDH2 inhibitors as antidipsotropic or alcohol-aversive agents (Keung, 2003). As our understanding of the roles played by the various ALDH isozymes in disease states continues to expand, the rationale for the development of selective inhibitors of the individual isozymes becomes more apparent. The availability of such inhibitors, at minimum, would permit verification of the putative roles of the isozymes. Optimally, such inhibitors would be used to treat disease states in which ALDH activity is implicated in their pathophysiology (Hiltbrand et al., 2009; Yao et al., 2010; Zhang et al., 2005, 2011). This review summarizes the current state of knowledge about inhibitors of the ALDH superfamily with respect to their selectivity, efficacy, and structure-activity relationships and their applications in treating disease states.

II. The Aldehyde Dehydrogenase Superfamily of Enzymes

The human ALDH superfamily comprises 19 known NAD(P⁺)-dependent enzymes that irreversibly catalyze the oxidation of both endogenously and exogenously produced aldehydes to their respective carboxylic acids (Fig. 1). In 1998, a gene nomenclature based on peptide sequence identity was instituted such that 1) families within the superfamily shared more than 40% sequence identity and 2) members of the same subfamily shared more than 60% sequence identity. ALDH activity is constitutively expressed in mammalian tissues, with the highest level in the liver, followed by the kidney, uterus, and brain (Alnouti and Klaassen, 2008). This activity is typically a composite of one or more of the ALDH isozymes, and some cells can also be induced to express ALDH isozymes under conditions of stress (Rice et al., 2008).

A. Enzymatic Functions of Aldehyde Dehydrogenase Isozymes

During embryogenesis, many developmental genes are transcriptionally regulated by retinoic acid (RA), the active metabolite of vitamin A and RA receptors (Niederreither and Dollè, 2008). The ALDH1A subfamily comprises the primary ALDHs (ALDH1A1/-1A2/-1A3)
that synthesize RA from retinal and are therefore crucial in regulating RA signaling. These ALDH isozymes have a high affinity for the oxidation of both all-trans- and 9-cis-retinal, exhibiting a $K_m$ in the lower micromolar range (Yoshida et al., 1992; Chen et al., 2011a). In agreement with a developmental role, these isozymes are expressed in tissues during vertebrate development in a spatial-temporal fashion (Downes and Holmes, 1992; Grün et al., 2000). Some stem cells, such as those associated with hematopoiesis, possess higher ALDH activity than normal cells, a characteristic that can be exploited for the isolation of primitive stem cell populations (Storms et al., 1999; Storms et al., 2005). Such activity in hematopoietic stem cells mediates RA signaling and thereby serves to regulate the self-renewal and differentiation of these cells (Hess et al., 2006; Rice et al., 2008).

The ALDH2 isozyme is predominantly linked with acetaldehyde detoxification in the second step of alcohol metabolism. Other ALDHs, including ALDH1A1 and ALDH1B1, also contribute to acetaldehyde oxidation, albeit with lesser affinity than the ALDH2 isozyme (Wang et al., 2009; Stagos et al., 2010). A genetic polymorphism in the ALDH2 gene can result in a substantial decrease in its acetaldehyde metabolizing capacity. The alcohol flushing syndrome observed in East Asian populations is caused by acetaldehyde accumulation manifesting as a result of reduced ALDH2 activity associated with the expression of the ALDH2*2 in this population (Higuchi et al., 1995).

ALDH activity also supports cellular homeostasis through protection from reactive oxygen species generated under conditions of oxidative stress. In this context, ALDH1A1 and ALDH3A1 (also respectively referred to as lens and corneal crystallins) are the isozymes that defend ocular surface tissues from reactive oxygen species (Estey et al., 2007; Chen et al., 2009). In addition, they maintain the integrity of the lens and cornea through nonenzymatic activities, including direct absorption of harmful UV radiation or serving as chaperones to prevent aggregation of misfolded proteins (Estey et al., 2010). ALDH7A1 has been shown to protect cells against hyperosmotic stress by generating osmolytes, such as betaine, and simultaneously metabolizing toxic aldehydes derived from lipid peroxidation (Brocker et al., 2010; Brocker et al., 2011).

ALDHs have the capacity to influence neural function, particularly in dopaminergic nerves. Both ALDH1A1 and ALDH2 have been implicated in dopamine metabolism. Inhibition of these isozymes leads to the accumulation of neurotoxic dopamine metabolites, such as 3,4-dihydroxyphenylacetaldehyde, that are thought to contribute to the pathogenesis of Parkinson’s disease (Burke et al., 2003; Marchitti et al., 2007; Allen et al., 2010). Dopaminergic pathways are involved in the reinforcing effects of cocaine addiction. Inhibition of ALDH2 suppresses cocaine-seeking behavior in conditioned rats through a 3,4-dihydroxyphenylacetaldehyde-dependent decrease in dopamine synthesis (Yao et al., 2010). Likewise, ethanol consumption by rodents has been shown to be reduced by ALDH inhibitor treatment through a mechanism independent of increases in systemic levels of acetaldehyde (Keung et al., 1995) and potentially involving suppression of central dopamine release (Arolfo et al., 2009). Such a central nervous system mechanism may contribute to the low incidence of alcohol consumption/addiction observed in subjects harboring the ALDH2*2 genetic variant that encodes the inactive

![Fig. 1. The ALDH superfamily of enzymes. Clustering dendrogram depicting the evolution of mammalian ALDHs from a single gene, their human chromosomal location, preferred substrate, and available X-ray crystal structures from the Research Collaboratory for Structural Bioinformatics (RCSB-PDB) database. * substrate for hydrolase reaction of ALDH1L2 (Strickland et al., 2011). [Modified from Marchitti SA, Deitrich RA, and Vasiliou V (2007) Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol Rev 59:125–150. Copyright © 2007 American Society for Pharmacology and Experimental Therapeutics. Used with permission.]

ALDH2 enzyme. In addition, the isozyme ALDH5A1, also known as mitochondrial succinic semialdehyde dehydrogenase, is an important regulator of GABA metabolism (Kim et al., 2011a). It is believed that, through their metabolic functions, ALDHs have a significant involvement in neuroprotection (Marchitti et al., 2007).

Finally, several ALDH isozymes have been discovered to have both regulatory as well as metabolic roles in cancer. Cancer stem cell (CSC) populations have elevated ALDH activity (Tanei et al., 2009), which can confer resistance to selected anticancer agents by metabolic inactivation. Such interference with chemotherapy is speculated to be a cause of relapse in cancer patients (Honoki et al., 2010; Su et al., 2010; Kim et al., 2011b). Because of its high expression, ALDH activity is used as a specific marker for CSCs through the ALDEFLUOR assay (Alison et al., 2010); however, it is important to recognize that the high ALDH activity observed in CSCs are probably due to multiple or distinct ALDH isozymes, the contribution of each depending on the specific type of the tumor (Marcato et al., 2011). For example, ALDH7A1 was recently implicated in facilitation of prostate cancer metastasis (van den Hoogen et al., 2011) whereas ALDH1B1 was found to be highly induced in human colonic adenocarcinoma (Chen et al., 2011b).

B. Structure and Catalysis of Aldehyde Dehydrogenase

The ALDH enzymes share a wide range of common physiological functions and substrates. Nevertheless, each of the isozymes has evolved distinct substrate specificities (Wang et al., 2009). Exploiting differences in the catalytic active site architecture would then facilitate the design of new inhibitors selective for each isozyme.

Certain classes of the ALDH isozymes have been co-crystallized with their preferred substrates, a process that has facilitated characterization of the active site structure (Liu et al., 1997; Cobessi et al., 2000; Larson et al., 2005; D’Ambrosio et al., 2006; Lowe et al., 2008). Most isozymes share the same catalytic mechanism for both dehydrogenase and esterase activity, except for ALDH6A1, which uses CoA as a cofactor rather than NAD(P)⁺ (Kazmi et al., 1992; Xiao et al., 2009). This feature of the ALDH superfamily probably relates to the following catalytic residues being highly conserved: Cys302, Lys192, and Glu268. Mammalian ALDHs function as either homotetramers or homodimers, with an active site in each monomer. The tetramers may display either full- or half-site reactivity with substrate, depending on the pH and the presence of divalent cations (Takahashi et al., 1981; Weiner and Takahashi, 1983; Rodriguez-Zavala and Weiner, 2002). In general, each of these monomers comprise 500 to 600 amino acids, although there are some classes, such as ALDH1A1, -1A2, -1L1, and -1L2, that have up to 800 or 900 amino acids (Min et al., 1988; Strickland et al., 2011). Crystallographic studies indicate that the ALDH monomer across all classes share high homology in three distinct functional regions: coenzyme (NAD) binding domain, catalytic domain, and oligomerization domain (Fig. 2, A and B) (Liu et al., 1997; Steinmetz et al., 1997; Colby et al., 1998; Cobessi et al., 2000; D’Ambrosio et al., 2006).

Site-directed mutagenesis experiments have revealed that catalysis occurs in five steps (illustrated in Fig. 3A) (Hempel et al., 1999): 1) activation of the catalytic Cys302 via a water-mediated proton abstraction by Glu268, 2) consequent nucleophilic attack on the electrophilic aldehyde by the thiolate group of Cys302, 3) formation of a tetrahedral thiohemiacetal intermediate (deacylation) with concomitant hydride transfer to the pyridine ring of NAD⁺, 4) hydrolysis of the resulting thioester intermediate, and 5) dissociation of the reduced cofactor and subsequent regeneration of the enzyme by NAD⁺ binding. Glu268 functions as a general base required to activate the Cys302 through deprotonation, leading to the thiohemiacetal formation preceding the deacylation step (Wang and Weiner, 1995; Sheikh et al., 1997). It was proposed that the first and the fourth steps require an ordered water molecule bound to the side chain of Glu268 (Fig. 2C) (i.e., to facilitate both the deprotonation of Cys302 and the subsequent hydrolysis of the thioester intermediate). The active site is located at the base of hydrophobic tunnel 12 Å from the surface of the enzyme, near the tetrameric interface and opposite the cofactor binding site (Fig. 4). Residues lining this tunnel are believed to confine the substrate specificity of each isozyme. The NAD⁺ cofactor is bound to the enzyme through 10 hydrogen bonds, four of which involve two residues, Lys192 and Glu399, that are highly conserved in all ALDH isozymes (Ni et al., 1997). Both residues make two hydrogen bonds each, one to the adenosine ribose and the other to the nicotinamide ribose of NAD⁺. Site-directed mutagenesis of these residues in ALDH2 changes the rate-limiting step of the reaction from the deacylation step to the hydride transfer step. Lys192 mutants alter substrate specificity from aliphatic to aromatic aldehydes in ALDH2 (Ni et al., 1997). The ALDH1, ALDH2, and ALDH3 classes of isozymes differ substantially in the rate-limiting step depending on the effect of cofactor binding, presence of divalent ions, and pH of the reaction (Takahashi et al., 1981; Perez-Miller and Hurley, 2003). Reduced cofactor release is the rate-limiting step for ALDH1A1, whereas for ALDH3A1, it is the hydride transfer.

The proposed mechanism of the esterase activity of the ALDHs (shown in Fig. 3B) shares some common properties with the dehydrogenase activities. For example, it requires the activated Cys302 residue and Glu268 but does not require the presence of NAD(P⁺). However, the impact that the presence of cofactor has on the reaction is variable and isozyme-dependent. For most ALDH1 and ALDH2 isozymes, addition of cofactor initiates the esterase reaction, an effect thought to occur through increased nucleophilicity of the active site.
Cys302 (Takahashi et al., 1981). However, recent studies on ALDH2 relate the effect of cofactor to that of Alda-1 (mentioned earlier as an activator of ALDH2 and ALDH2*2), where the presence of either cofactor or Alda-1 initiates the esterase reaction by increasing the frequency of productive encounters with the active site Cys302 (Perez-Miller et al., 2010). It is likely that the variable effects of cofactor, like the variable effects of mutations on conserved active site residues, are related to the differences among the ALDH isozyme in their rate-limiting steps.

The genetic polymorphism ALDH2*2 affects 50% of the Asian population and results in a diminution in ALDH2 activity (Goedde and Agarwal, 1987; Higuchi et al., 1995). This is a result of a substitution of Glu487 for Lys487. The failure of Lys487 to form hydrogen bonds with Arg264 in its own subunit (or with Arg475 in its dimer subunit) results in a weaker NADH binding site, a situation that ultimately affects the kinetic properties of the enzyme (Larson et al., 2007). Mechanistic studies have revealed differences between the ALDH2 and ALDH3 isozymes with respect to the rate-limiting step, the function of conserved Glu333 and Glu209 residues and the differential effect of NADH binding on the esterase activity (Mann and Weiner, 1999). Such isozyme-specific differences in interacting residues, along with differences in oligomeric state, inhibition mechanisms, and substrate specificity, could be exploited for the development of selective inhibitors (Batt and Crow, 1989; Yoshida et al., 1998).

III. Clinical Applications of Aldehyde Dehydrogenase Inhibitors

The current development of ALDH inhibitors is being driven by emerging clinical needs. It has to be noted, however, that pharmacological inhibitors have been developed for only 3 of the 19 ALDH isozymes. These are the enzymes involved in the metabolism of alcohol (ALDH2) and the anticancer oxazaphosphorine drugs (ALDH1A1 and ALDH3A1).

Alcohol-related disease is the third leading lifestyle-related cause of death in the United States, claiming approximately 23,000 lives in 2006 alone (Heron et al., 2009). In 2009, alcohol abuse claimed 2.3 million lives internationally (Mokdad et al., 2004). In the liver, ethanol is first metabolized to acetaldehyde by alcohol dehydrogenases and cytochrome P450 2E1 (Lieber, 1994). The acetaldehyde thus produced is oxidized mainly by mitochondrial ALDH2 (Weiner, 1979; Goedde and Agarwal, 1987; Batt and Crow, 1989; Soyka and Rösner, 2010). The unpleasant alcohol flushing syndrome experienced by persons with the ALDH2*2 polymorphism renders a large population of Asians intolerant of what might be considered “normal” levels of alcohol consumption. This observation led to the development of mole-
FIG. 3. A, mechanism of aldehyde oxidation. 1, activation of the catalytic Cys302 by the ordered water molecule and Glu268 through proton abstraction. 2, nucleophilic attack on the carbonyl carbon of the aldehyde by the thiolate group of the catalytic Cys302. 3, formation of the tetrahedral thiohemiacetal intermediate (deacylation) and hydride transfer from the tetrahedral thiohemiacetal intermediate to the pyridine ring of NAD\(^+\). 4, hydrolysis of the resulting thioester intermediate. 5, dissociation of the reduced cofactor and subsequent regeneration of the enzyme by NAD\(^+\) binding.

B, proposed mechanism of ester hydrolysis. 1, catalytic cysteine residue is activated by hydrogen abstraction from a basic residue (Glu268) in catalytic site. 2, thiolate ion attacks the substrate p-nitrophenyl acetate leading to oxyanion intermediate formation. 3, the intermediate rearranges and nitrophenolic group leaves. 4, Glu268 residue abstracts hydrogen from nearby ordered water molecule, making it a nucleophile. It attacks the carbonyl in the thioacyl enzyme complex. 5, formation of the tetrahedral intermediate that again rearranges to release acetic acid and free enzyme.
cules that selectively inhibit ALDH2 with the idea of creating drugs that would render a person vulnerable to acetaldehyde-associated symptoms after alcohol consumption (e.g., alcohol-aversive drugs for alcoholics or antidipsotropic agents) (Mason and Heyser, 2010; Rösner et al., 2010; Soyka and Rösner, 2010). The capacity of ALDH to metabolize acetaldehyde is important from a toxicological standpoint because accumulation of acetaldehyde leads to formation of protein adducts (from lipid peroxidation) and subsequent loss of critical physiological functions. For example, in ethanol-induced cardiac toxicity, accumulation of acetaldehyde increases myocardial susceptibility to ischemia reperfusion injury (Wang et al., 2008; Chen et al., 2010).

An important clinical issue in cancer treatment is the development of chemotherapeutic drug resistance. Although most patients with advanced disease respond to initial chemotherapy, the majority of them has a relapse within 5 years of completing treatment; one third of patients are intrinsically resistant. It is now well accepted that CSCs, a small subset of cancer cells, can be resistant to chemotherapy and thereby promote cancer relapse by acting as a source of tumor cell populations (Honoki et al., 2010; Su et al., 2010). A key biochemical feature of CSCs is high ALDH activity, as illustrated in numerous recent studies documenting the profound tumorigenic potential of ALDH-expressing cells (Su et al., 2010; Chen et al., 2011b; Kim et al., 2011b). In addition, increased activity of ALDH1A1 and ALDH3A1 isozymes has been associated with the development of resistance of tumor cell populations to oxazaphosphorine anticancer drugs, such as cyclophosphamide and procarbazine (Sládek, 1999; Giorgianni et al., 2000; Zhang et al., 2005; Tanei et al., 2009; Honoki et al., 2010). The role of ALDH in the resistance mechanism is supported by the observation that the potency of these drugs are increased when ALDH activity is inhibited (Croker and Allan, 2011). Based on these observations, ALDH isozymes have been proposed as new pharmacological targets for the more effective treatment of cancer. In this regard, new agents are being developed and tested as ALDH inhibitors, particularly targeting the ALDH1A1 and ALDH3A1 isozymes (Parajuli et al., 2011).

Although inhibition of individual ALDH isozymes represents a potentially fruitful approach to treating disease, it is important to recognize that an accumulating body of literature suggests that activation of ALDH may produce beneficial effects in specific disease or therapeutic conditions. For example, by protecting ALDH2 from inactivation, Alda-1, a small-molecule activator of ALDH, prevents the tolerance that normally attends long-term nitroglycerin therapy (Perez-Miller et al., 2010). Such tolerance is a growing concern among physicians treating ischemic and congestive heart disease. In addition to playing a central role in the vasodilator actions of nitroglycerin, ALDH2 may be important in...
protecting ischemic myocardium. By preventing ALDH2 inactivation by ischemia-associated 4-hydroxy-2-nonenal, Alda-1 reduces the extent of infarction-induced injury (Budas et al., 2009, 2010; Chen et al., 2010). Patients suffering from Fanconi’s anemia are more vulnerable to acetaldehyde-induced DNA damage (Alter et al., 2005; Joenje, 2011). Given the important role of ALDH2 in metabolizing toxic aldehydes, it is reasonable to speculate how the administration of an ALDH activator would be beneficial in these patients. The fact that activation or inhibition of ALDH enzymes can have beneficial effects (depending on the specific disease or treatment conditions) underscores the need for a greater understanding of the role played by each isozyme in specific diseases. Such knowledge will allow the prediction of beneficial and deleterious effects of any developed inhibitors or activators.

### IV. Pharmacological Inhibitors of Aldehyde Dehydrogenase Enzymes

The following 14 ALDH inhibitors will be discussed in their alphabetic order. Their mechanisms of action, isozyme selectivity, inhibition potency, and other features are summarized in Table 1.

**A. 4-Amino-4-methyl-2-pentyne-1-al**

4-Amino-4-methyl-2-pentyne-1-al (AMPAL) and 2-methyl-5-(methylsulfanyl)-5-oxopentan-2-aminium are two irreversible inhibitors of the ALDH1 and ALDH3 isozymes. AMPAL is also known for its antitumor activity and thus substantiates the relationship between resistant neoplasticity and high ALDH activity (Quemener et al., 1989). Rat JM2 hepatoma cells exhibit high ALDH1 and ALDH3 activity. Two analogs of AMPAL, 4-methyl-1-(methylsulfanyl)-4-(2,2,5,5-tetramethylpyrrolidin-1-yl)pent-2-yn-1-one and 4-(dimethylamino)-4-methyl-1-(methylsulfanyl)pent-2-yn-1-one, inhibited the ALDH activity in these cells and elicited significant cell growth inhibition (Canuto et al., 2001). The analogs differ from each other in the substituent at the C4 position in AMPAL. This evidence establishes possible role of ALDHs in stall- ing growth in tumor cells.

**B. Benomyl**

Benomyl (methyl-[1-[(butylamino)carbonyl]-1H-benimidazol-2-yl]carbamate) is a benimidazole fungicide that is selectively toxic to microorganisms and invertebrates (Somerville, 1986). This agent is a potent inhibitor of mouse liver mitochondrial ALDH in vitro and in vivo (Staub et al., 1999). When administered to mice in vivo, benomyl specifically inhibits ALDH2 (IC_{50} 24 μmol/kg) (Staub et al., 1998). Such selectivity for ALDH2 is not apparent in vitro, suggesting that this benomyl is biotransformed in vivo to intermediates that are more potent inhibitors of ALDH2.

Insight into the mechanisms involved in the in vivo formation of mouse ALDH2 inhibitory metabolites originated from studies describing the presence of S-(N-butylcarbamoyl)GSH (GSBT) in bile and S-(N-butylcarbamoyl)cysteine (CysBT) and N-acetyl-S-(N-butylcarbamoyl)cysteine in urine (Axness and Fleeker, 1979). These metabolites primarily are derived from the butylcarbamyl moiety, which gives clues to the nature of metabolites mediating the inhibition. Identification of these metabolites suggest that GSBT and CysBT are activated by β-lyase to inhibitors (Fig. 5). S-Methyl-N-butylthiocarbamate (MBT) is one such metabolite identified in the liver as a transient inhibitory intermediate and found to be bioactivated to the final inhibitors by members of the microsomal cytochrome P450 family (Staub et al., 1998).

On the basis of these observations, a six-step activation pathway for benomyl metabolism and ALDH inhibition has been postulated. The first step involves spontaneous release of butyl isocyanate (BIC), another potent inhibitor of mitochondrial ALDH2, from the parent compound. The other product, methylbenzimidazolecarbamate, did not inhibit the enzyme to the same extent as the parent compound and thus was not pursued. Once released, BIC conjugates with GSH to form GSBT, which is hydrolyzed by γ-glutamyltranspeptidase and cysteine to CysBT. This is subsequently converted to N-butylthiocarbamic acid by β-lyase. Methylcylation of N-butylthiocarbamic acid by S-methyltransferase forms the penultimate inhibitor MBT, which is then subject to P450-mediated N-hydroxylation or sulfoxidation, the products of which have the potential to carbamoylate the active site Cys302 of ALDH2 (Axness and Fleeker, 1979; Staub et al., 1998, 1999). The earlier metabolites, GSBT, NAcSBT, and Cys-BT, from the GSH pathway were all found to inhibit mitochondrial ALDH2 in vitro, suggesting that there are yet other metabolites of benomyl acting as inhibitors. This suggests the need for structure-activity relationship studies that need to be conducted on these metabolites.

**C. Chloral**

Trichloroacetaldehyde monohydrate (or chloral) was among the most potent hypnotic agents first synthesized. Early on, it was recognized that, when ingested with alcohol, chloral elicited a rapid induction of sleep, often referred to as the “Mickey Finn” effect. Chloral is a competitive substrate of ALDH with a slow k_{cat} and IC_{50} values ranging from 1 to 10 μM (Poon et al., 2002). In vivo, its metabolites include trichloroacetic acid, proving that it functions as a substrate (Poon et al., 2000) there by being capable of inhibiting the metabolism of other aldehydic substrates of ALDHs. The mechanism by which it inhibits ALDH is thought to involve reversible thiohemiacetal formation with Cys302 in the active site.
<table>
<thead>
<tr>
<th>Inhibitor</th>
<th>Active Metabolite</th>
<th>Type of Inhibition</th>
<th>IC&lt;sub&gt;50&lt;/sub&gt;</th>
<th>Other Features</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ampal</td>
<td>Thioampal</td>
<td>Irreversible</td>
<td>μM</td>
<td>N.A.</td>
<td>In rat hepatoma cells (JM2), thioampal derivatives inhibited ALDH1 and ALDH3 isoenzymes significantly. Also noted were growth inhibition and antitumor activity by these derivatives. Quemener et al., 1989; Canuto et al., 2001; Quash et al., 2008</td>
</tr>
<tr>
<td>Benomyl</td>
<td>MBT</td>
<td>Irreversible</td>
<td>μM</td>
<td>N.A.</td>
<td>MBT showed IC&lt;sub&gt;50&lt;/sub&gt; of 0.23 μM with mouse ALDH2, with activation by microsomes. The activation is inhibited by P450 inhibitor. Axness and Fleeker, 1979; Staub et al., 1998, 1999</td>
</tr>
<tr>
<td>Citral&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Neral and geranial</td>
<td>Reversible</td>
<td>N.A.</td>
<td>N.A.</td>
<td>Geranial showed positive cooperativity with hALDH2; n = 2–2.5; Citral K&lt;sub&gt;i&lt;/sub&gt; for Rat ALDH2 = 360 nM Boyer and Petersen, 1991; Kikonyogo et al., 1999</td>
</tr>
<tr>
<td>Chloral hydrate&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Chloral hydrate</td>
<td>Reversible</td>
<td>1–10</td>
<td>N.A.</td>
<td>Also inhibits esterase activity noncompetitively (K&lt;sub&gt;i&lt;/sub&gt; = 19 μM) with NAD⁻ Lee et al., 1992; Nagasawa et al., 1995; Rekha et al., 1998</td>
</tr>
<tr>
<td>Chlorpropamide analogs NPI-1 API-1</td>
<td>NPI-1</td>
<td>Irreversible</td>
<td>50</td>
<td>N.A.</td>
<td>Inhibits the esterase activity. Displays mutagenicity and gonadotoxicity. Marchner and Tottmar, 1983; Michelot, 1992</td>
</tr>
<tr>
<td>Coprine</td>
<td>1-Amino cyclopropanol</td>
<td>Irreversible</td>
<td>28</td>
<td>0.29</td>
<td>Requires activation by catalase. Also inhibits catalase activity. Liver injury reported with simultaneous consumption of alcohol. Shirota et al., 1987; Nagasawa et al., 1990</td>
</tr>
<tr>
<td>Cyanamide</td>
<td>HNO</td>
<td>Irreversible</td>
<td>1.3</td>
<td>0.029</td>
<td>No activation required. Confers sensitivity to cyclophosphamide-resistant cells. Croker and Allan, 2011</td>
</tr>
<tr>
<td>Daidzin</td>
<td>Daidzin</td>
<td>Reversible, competitive</td>
<td>1.3</td>
<td>0.55</td>
<td>Structure analogs are being developed as antidipsotropic agents. Love et al., 2008; Arolfo, 2009</td>
</tr>
<tr>
<td>Gossypol</td>
<td>Gossypol</td>
<td>Reversible</td>
<td>75</td>
<td>45 7.5 (competitive)</td>
<td>Inhibits several other dehydrogenase enzymes. Interacts with alcohol in system to form a toxic metabolite, sufficient for aversion from drinking. Known for antitumor, antiviral, and antiparasitic activities. Burgos et al., 1986; Rekha and Sladek, 1997; Pang et al., 2011</td>
</tr>
</tbody>
</table>
Because of the powerful electron-withdrawing properties of the \( \text{Cl}_3\text{C} \) group, the hydride transfer step of the catalytic mechanism is likely to be impaired.

### D. Chlorpropamide analogs

The potential of oral hypoglycemic agents, including chlorpropamide and tolbutamide, to impair the oxidation of acetaldehyde in patients ingesting alcohol-containing beverages was well documented 5 decades ago (Grün et al., 2000). Numerous reports thereafter described the occurrence of malaise and facial flushing in 15 to 23% of human subjects taking these oral hypoglycemic agents after alcohol ingestion (Yoshida et al., 1992). A study in mice suggested that coadministration of chlorpropamide or tolbutamide, to impair the oxidation of acetaldehyde in patients ingesting alcohol-containing beverages was well documented 5 decades ago (Grün et al., 2000). Numerous reports thereafter described the occurrence of malaise and facial flushing in 15 to 23% of human subjects taking these oral hypoglycemic agents after alcohol ingestion (Yoshida et al., 1992).

### E. Citral

Citral (3,7-dimethyl-2,6-octadienal) belongs to a class of volatile \( \alpha,\beta \)-unsaturated aldehydes that occur naturally in herbs and citrus fruits. It can be found in synthetic products such as food additives, cosmetics, and detergents. Like other \( \alpha,\beta \)-unsaturated aldehydes (e.g., acrolein, crotonaldehyde, and 4-hydroxynonenal), it is more of a slow, noncompetitive inhibitor than a strict inhibitor of ALDH1, ALDH2, and ALDH3 isozymes (Boyer and Petersen, 1991; Kikonyogo et al., 1999).
eral occurs as a 1:2 mixture of cis and trans isomers, termed neral and geranial, respectively; geranial is the preferred isomer for inhibition of the ALDH1 isozyme (Kikonyogo et al., 1999). For ALDH2, neral shows Michaelis-Menten kinetics and geranial shows positive cooperativity. The \( K_m \) for citral with ALDH3 is extremely low compared with ALDH1 and ALDH2, suggesting that it might be a specific inhibitor of this isozyme (Kikonyogo et al., 1999). Geranial is preferentially metabolized by ALDH1 because it has a very high \( V_{max}/K_m \) ratio, probably as a result of its structural resemblance to all-trans retinaldehyde (Kikonyogo et al., 1999), the natural substrate for ALDH1. Citral has been used to study vertebrate development as a result of its capacity to

---

**Fig. 5.** Benomyl and its active metabolites. Benomyl is metabolized to BIC. BIC is then conjugated with GSH to form GSBT. Under the action of \( \gamma \)-glutamyltranspeptidase, GSBT is transformed to Cys-BT. \( \beta \)-Lyase then converts Cys-BT to N-butylthiocarbamic acid, which is then converted to MBT. Under the action of P450s, MBT gives rise to various sulfoxide and N-hydroxyl products that inhibit the ALDH2 active site through carbamylation of the active cysteine. [Adapted from Staub RE, Quistad GB, and Casida JE (1998) Mechanism for benomyl action as a mitochondrial aldehyde dehydrogenase inhibitor in mice. *Chem Res Toxicol* 11:535–543. Copyright © 1998 American Chemical Society. Used with permission.]

inhibit retinoic acid synthesis (Kronmiller et al., 1995; Tanaka et al., 1996).

**F. Coprine**

Coprine is the active ingredient of the mushroom *Coprinopsis atramentaria*. Minor poisoning incidents associated with ingestion of the mushrooms with alcohol, termed coprinus syndrome, led to the development of the active compound for use as an antidipsotropic agent. Coprine does not inhibit ALDH2 in vitro but does so in vivo as a consequence of its hydrolysis to its active metabolite, 1-amino cyclopropanol (Tottrmar and Lindberg, 1977), which inhibits ALDH2 irreversibly through electrophilic attack and covalent modification of the Cys302 thiol (Marchner and Tottmar, 1983). In vitro, the rate of inactivation seemed to increase at higher concentrations of NAD⁺ in solution, suggesting that a conformational change in ALDH makes it more amenable for the inhibitor to interact with its active site. The esterase activity of ALDH is also inhibited, albeit to a lesser extent compared with the dehydrogenase activity (Marchner and Tottmar, 1983). Unlike disulfiram (see below), it does not inhibit dopamine β-hydroxylase (Carlsson et al., 1978; Tottmar and Hellstrom, 1979). Despite its potency at inhibiting ALDH activity, mutagenic and gonadotoxic side effects prevented further pursuit of this compound as a candidate for drug development (Michelot, 1992).

**G. Cyanamide**

Cyanamide (in the form of calcium carbimide citrate salt) is an ALDH inhibitor used therapeutically as an alcohol-aversive agent (Temposil) in Europe, Canada, and Japan. It is a prodrug that requires conversion to its active metabolite (Fig. 7). Bioactivation requires catalase and H₂O₂ to generate N-hydroxycyanamide, which spontaneously decomposes to cyanide (Shirot a et al., 1987) (produced at much lower concentrations than that required to elicit toxicity) and nitroxy l, the latter serving as the inhibitor of ALDH (Nagasawa et al., 1990). The mode of inhibition was found to be both reversible (via intersubunit disulfide formation) and irreversible (via sulfinamide formation) depending on the pH of inactivation (DeMaster et al., 1998) via the formation of an N-hydroxysulfinamide intermediate. Given that nitroxy l reacts with thiol proteins, it may be predicted that nitroxy l treatment could lead to depletion of cellular GSH. However, contrary to expectations, extremely low concentrations of nitroxy l deactivate select thiol proteins, such as glyceraldehyde 3-phosphate dehydrogenase, without altering the cellular GSH/GSSG ratio (DeMaster et al., 1998; Paolocci et al., 2007). Pro-drugs of nitroxy l, such as derivatives of N,O-diacylated N-hydroxyaryl sulfonamide (Fukuto et al., 1992) and N-acyloxy-O-arenesulfonylated benzene carboximidic acid (Lee et al., 2001), are being developed, albeit with more emphasis on their use as vasodilators (Nagasawa et al., 1995) that are bioactivated by the esterase activity of the ALDH enzyme. In the treatment of alcohol Addiction, cyanamide is a second-line drug relative to disulfiram owing to its greater capacity to induce liver injury compared with disulfiram (Tamai et al., 2000).

**H. Daidzin (antioxidant Isoflavone)**

Daidzin, daidzein, and puerarin are phytochemicals derived from the Chinese edible vine *Pueraria lobata*. They have been used for cancer prevention and antidipsotropic treatments in ancient Chinese medicine (Keung and Vallee, 1993; McGregor, 2007). Daidzin (7-O-glucosyl-4'- hydroxyisoflavone) (Fig. 8), and its structural analogs are among the very few highly potent inhibitors of the ALDH2 isozyme (IC₅₀, 80 nM) (Lowe et al., 2008). Structural requirements of these molecules for ALDH2 inhibition include a polar 4'-substituent with hydrogen binding capacity, such as –NH₂ and –OH, and an isoflavone group that blocks the substrate binding site in the hydrophobic cleft (Lowe et al., 2008). Based on these
observations, new analogs of daidzin have been developed as highly selective, reversible inhibitors of ALDH2. For example, CVT-10216 (Fig. 8) shows an IC₅₀ of 29 nM for ALDH2 and 1300 nM for ALDH1 (Arolfo et al., 2009).

An additional advantage of these inhibitors is their minimal effect on monoamine oxidase (Yao et al., 2010). CVT-10216 has also seen application in cocaine addiction, where inhibition of ALDH2 causes aberrant dopamine metabolism, leading to the production of a metabolite that suppresses dopamine synthesis and cocaine self-administration in animal models (Yao et al., 2010).

I. 4-(Diethylamino)benzaldehyde

4-(Diethylamino)benzaldehyde (DEAB) seems to be more of a slow competitive substrate (like citral and chloral) than a classic inhibitor of ALDH isozymes (Russo et al., 1988), although the precise mechanism of inhibition remains to be elucidated. It has been used as an ALDH1-selective inhibitor for repressing retinoic acid synthesis in studies investigating the role of retinoic acid in abnormal embryonic development in vertebrates (van den Hoogen et al., 2011). The DEAB derivative 4-(N,N-dipropylamino)benzaldehyde is also a competitive inhibitor of retinal oxidation (Russo et al., 2002). Despite the use of DEAB as a potent inhibitor of ALDH1, its specificity has not been completely ascertained. When administered in doses of 50 and 100 mg/kg to mice, DEAB increased the blood acetaldehyde concentration and inhibited the fraction of ethanol converted to acetic acid by 32.5 and 67.5%, respectively (Mahmoud et al., 1993). In recent years, a commercial Aldefluor assay has been developed and widely used to identify stem cells from normal and cancerous tissues on the basis of the observation that these cells exhibit high ALDH activity (Moreb et al., 2007). In this assay, the fluorescence of a cell membrane-permeable substrate is enhanced by ALDH activation of the molecule. In this assay, DEAB treatment is used as a control to define the contribution of ALDH activity to the fluorescence changes (Storms et al., 1999).

J. Disulfiram

Disulfiram (tetraethylthioperoxydicarbonic diamide), commercially known as Antabuse, has been used since 1948 as an alcohol-aversive agent in the treatment of alcoholism (Bell and Smith, 1949). Consumption of alcohol by patients given therapeutic doses of disulfiram results in acetaldehyde accumulation, the physiological consequences of which include low blood pressure, tachycardia, facial flushing, nausea, and vertigo (Bell and Smith, 1949). These symptoms, collectively called disulfiram ethanol reaction (Tottmar and Hellstrom, 1979; Marcato et al., 2011), serve as the means by which the individual is discouraged from indulging in alcohol intake. Disulfiram itself inhibits ALDH1A1 more potently that it does ALDH2 (Moore et al., 1998), which led to some early confusion as to the identity of the enzyme inhibited in vivo. This is attributed to the fact that the hydrophobic tunnel in the enzyme’s architecture through which the substrate enters is larger in ALDH1 and therefore capable of accommodating disulfiram, a bulky molecule, more effectively (Moore et al., 1998). In the 1980s, cephalosporin antibiotics had been known to cause alcohol flushing reactions in a manner similar to that of disulfiram (Fromtling and Gadebusch, 1983). The disulfide bond in the 5,5′-dithiobis(1-methyltetrazole) side chain of these agents is shown to mediate the inactivation of the catalytic Cys302 of ALDH1A1 enzyme in vitro, giving clues to the mode of enzyme inhibition (Kitson, 1986).

The molecular mechanism of ALDH inhibition is mediated by metabolic products of disulfiram (Fig. 9). The first of these involves the reduction of the disulfide bond and concurrent liberation of diethyldithiocarbamate (DDTC), an inhibitor of ALDH in vivo but not in vitro (Deitrich and Erwin, 1971; Kitson, 1975; Vallari and Pietruszko, 1982; Kitson, 1983; Lipsky et al., 2001). DDTC is converted by hepatic thiol methyltransferases to S-methyl-N,N-diethyldithiocarbamate (DETC) and S-methyl-N,N-diethyldithiocarbamate (Me-DDTC), both potent inhibitors of mitochondrial ALDH2 in vivo. Subsequent P450-catalyzed oxidation metabolites of DETC and Me-DDTC, including DETC-sulfoxide (DETC-SO) and S-methyl-N,N-diethyldithiocarbamate-sulfoxide (Me-DDTC-SO), also inhibit mitochondrial ALDH (Hart and Faiman, 1992; Mays et al., 1996, 1998) (Fig. 9). The inhibition induced by all of these compounds is irreversible in nature because of carbamylation of the catalytic Cys302 residue (Staub et al., 1999; Lipsky et al., 2001; Shen et al., 2001). Glutathione blunts the inhibition caused by DETC-SO and DETC-SO₂ but does not affect inhibition induced by
Me-DDTC-SO, which is relatively more potent (Lam et al., 1997; Mays et al., 1998). This gives rise to the intriguing possibility that, if intracellular levels of GSH are sufficient to mitigate the inhibitory action of the metabolites, Me-DDTC-SO may perhaps be a better candidate for specific inhibition of ALDH2, given its ability to overcome GSH scavenging (Mays et al., 1998).

In addition to being used as an antidipsotropic agent, disulfiram has found a new therapeutic use in treating cocaine addiction via an ALDH-independent mechanism. This is thought to involve disulfiram inhibition of dopamine β-hydroxylase (Barth and Malcolm, 2010; Schroeder et al., 2010), the copper-dependent enzyme required for metabolism of dopamine to norepinephrine in noradrenergic neurons. The resultant disulfiram-induced decrease in norepinephrine release from noradrenergic nerves impinging on midbrain dopaminergic neurons is thought to reduce excitation of these dopaminergic neurons and thereby attenuate the cocaine-induced euphoria (Gaval-Cruz and Weinshenker, 2009). These inhibitory effects are attributed to the copper-chelating activity of the disulfiram metabolite DDTC. Disulfiram inhibits other copper-dependent enzymes, such as carboxylesterase and cholinesterase (Zemaitis and Greene, 1976). This same copper-chelating action is thought to induce proteasome inhibition and subsequent cancer cell apoptosis (Wang et al., 2011), leading to the proposal that disulfiram could serve as an anticancer therapy (Lin and Lin, 2011). The observed inhibition by disulfiram of prostate cancer cell growth, together with its ability to act as a DNA-demethylating agent (Lin et al., 2011) support this proposed use. Clinical trials are currently under way that evaluate its ability to repress cancer growth (Kona et al., 2011; Lin and Lin, 2011).

K. Gossypol

Gossypol, a terpenoid aldehyde extracted from cottonseed, was traditionally used in Chinese medicine as a male contraceptive. More recently, ongoing investigations have focused on its antitumor activity (Cengiz et al., 2010) as a result of documented antineoplastic activity in human breast adenocarcinoma (Van Poznak et al., 2001; Van Poznak and Seidman, 2002; Pang et al., 2011) and metastatic prostate cancer (Huang et al., 2009). Inhibition of the apoptosis regulatory proteins B-cell lymphoma-extra-large and B-cell lymphoma 2 was thought to underlie gossypol’s beneficial effects in cancer treatment (Huang et al., 2010). However, this compound inhibits ALDH and other NAD(P)H-catalyzed oxidations, such as aldose reductases, lactate dehydrogenases, and malate dehydrogenases (Burgos et al., 1986). With respect to ALDH-induced oxidation, gossypol acts as a noncompetitive inhibitor and shows relatively more selectivity for the ALDH3 isozyme than the ALDH1 and ALDH2 isozymes (Rekha and Sladek, 1997). It is noteworthy that the nature of inhibition was always competitive with respect to the cofactor involved but not the aldehyde substrate (Rekha and Sladek, 1997). This observation suggests that gossypol may interact with the cofactor binding site, which may underlie the commonality of inhibition of dehydrogenases. Gossypol does not inhibit the esterase activity of the ALDHs (Rekha and Sladek, 1997).

L. Kynurenine Metabolites

High tryptophan levels in patients with chronic fatigue syndrome seemed to induce alcohol aversion (CasteII et al., 1999). This anecdotal evidence led researchers to look for possible ALDH inhibitors in tryptophan me-
tabolites. Four tryptophan metabolites in the kynurenine pathway (3-hydroxykynurenine, 3-hydroxyanthranilic acid, kynurenic acid, and indol-3-ylpyruvic acid), have been shown to inhibit rat liver mitochondrial ALDH2 (Badawy and Morgan, 2007). These agents are being developed as potential antidipsotropic treatments (Badawy et al., 2011).

M. Molinate

Molinate is a thiocarbamate derivative used as a rice pesticide. It was phased out because of its neurological and reproductive toxicity in rodents (Chen et al., 2011b). The mechanism of molinate-induced testicular toxicity is thought to be due to the binding of a sulfoxide metabolite of molinate to the protein hydrolase A, a carboxyl esterase found in Leydig cells (Jewell and Miller, 1998). Studies in human and rat liver microsomes and slices have shown that the sulfoxide metabolite and its sulfone are detoxified via glutathione conjugation to a far greater extent in humans than in rodents (Jewell and Miller, 1999). ALDH inhibitory activity of the thiocarbamate pesticides was surmised from the observation that farmers working with these pesticides were rendered alcohol-sensitive (Hart and Faiman, 1995). Molinate and its sulfoxide and sulfone metabolites have been shown to inhibit human recombinant ALDH2 in vitro (Allen et al., 2010). This occurs through an irreversible modification of the active site cysteine residue (Cys302) and thiocarbamate formation (Fig. 10) (Hjelle et al., 1981). Other thiocarbamate herbicides, such as pebulate, vernolate, butylate, triallate, and cycloate (and their metabolites) also inhibit ALDH activity (Quistad et al., 1994).

N. Nitroglycerin

Nitroglycerin or glycercly trinitrate (GTN) belongs to a class of potent organic nitrates used for almost a century to treat myocardial ischemia. GTN, along with other lower potency nitrates such as isosorbide dinitrate (ISDN), induces coronary vasodilation by a nitric oxide (NO)-dependent mechanism (Daiber et al., 2008). ALDH2 plays a significant role in the bioactivation of nitroglycerin to NO (Chen et al., 2002; Beretta et al., 2008) through a mechanism involving its esterase activity (Fig. 11). NO is cleaved at position 3 of GTN to produce 1,2-glyceryl dinitrate and nitrite (NO$_3^-$), whereas the enzyme itself gets inactivated through disulfide bridge formation with an adjacent cysteine. The NO$_3^-$ undergoes subsequent bioactivation by respiratory chain cytochrome oxidase to yield NO, which then induces vasodilation via a cGMP-dependent mechanism (Chen and Stamler, 2006; Daiber and Münzel, 2010). The vasodilatory effects of GTN decrease with long-term administration, a phenomenon called nitrate tolerance (Münzel et al., 2005; Daiber et al., 2010). NO produced from GTN can react with cellular superoxide to form peroxynitrite, which then oxidizes the catalytic thiol of ALDH2. Such inhibition of mitochondrial ALDH2 dehydrogenase activity also abolishes the esterase activity needed for activation of GTN, thus mitigating GTN-induced vasodilation.

Nitrate ester-based vasodilators such as ISDN are very attractive for the treatment of angina pectoris until the issue of GTN tolerance. The pathway responsible for the bioactivation of low-potency nitrates such as ISDN is through activation by P450 enzyme(s) in the endoplasmic reticulum (Münzel et al., 2005). It has been established that isosorbide esters also irreversibly inhibit the dehydrogenase and esterase activities of ALDH1 and ALDH2 (Mukerjee and Pietruszko, 1994; Pietruszko et al., 1995). Both of these isozymes are protected from inhibition in the presence of NAD$^+$ and chloral (the slow competitive substrate for ALDHs), suggesting that the isosorbide esters act as substrates (Mukerjee and Pietruszko, 1994). The restoration of ISDN vasodilator activity by strong reducing agents, such as DTT (but not cysteine or reduced GSH) consolidates the involvement of disulfide bond formation in its inhibitory action on ALDH (Mukerjee and Pietruszko, 1994; Daiber et al., 2004). However, Murphy et al. (2005) reported that ISDN does not inhibit ALDH2 and only selectively inhibits the ALDH3 isozyme (contradicting the above study); which, in turn, is capable of being reactivated by DTT. GTN was found to inhibit both isozymes, but only ALDH3 was reactivated by DTT (Murphy et al., 2005). This suggests that ALDH3 may be subject to a unique mode of inhibition by GTN that differs from the inhibition of ALDH2. A recent series of studies involving site-directed mutagenesis experiments led Wenzl et al. (2011) to propose three distinct pathways for GTN bioactivation by ALDH2. The dominant pathway involves the formation of nitrite and active site Cys (301 and 303) disulfide formation (Fig. 11). The second pathway involves irreversible inactivation of Cys302, promoted by Glu268. A third pathway was suggested by the fact that an ALDH2 triple mutant (E268Q/C301S/C303S)

C303S) produced superstoichiometric amounts of NO directly while forming a DTT-reducible species that proved relatively resistant to inactivation, although there is a need for further experimental validation. The experimental validation of the third pathway may open up possibilities of developing new vasodilators that can bypass the tolerance induced by GTN-mediated ALDH2 inactivation.

O. Pargyline

Pargyline (N-benzyl-N-methylprop-2-yn-1-amine) is an irreversible monoamine oxidase inhibitor used in the past as an antihypertensive agent. A clue that it affected ALDH was the manifestation of disulfiram-like reactions when patients taking pargyline ingested alcohol. Pargyline is activated by CYP2E1 in liver microsomes (Fig. 12) (Moridani et al., 2001) via N-depropargylation and N-demethylation (DeMaster et al., 1980) to yield propiolaldehyde, a highly reactive α,β-acyclic aldehyde that irreversibly inactivates ALDH2 (DeMaster and Nagasawa, 1978). Other minor pathways of P450-mediated N-debenzylation and N-oxidation have been suggested (Fig. 12). Whatever the pathway, propiolaldehyde and propargylamine seem to be the final effectors of ALDH inactivation. The mechanism of inactivation is thought to involve the irreversible modification of the catalytic cysteine (Cys302) via either carbamoylation or enone formation. The highly reactive propiolaldehyde certainly can react with cellular thiols, including those in ALDH enzymes, and cause depletion of GSH and subsequent lipid peroxidation (Moridani et al., 2001). Other in vivo metabolites of pargyline, such as benzylamine and propargylamine, also inhibit rat ALDH2 activity but do so indirectly via GSH depletion (DeMaster et al., 1986). Although propiolaldehyde has been found to be preferentially metabolized by ALDH2 (relative to ALDH1) (Ferencz-Biro and Pietruszko, 1984; Lebsack et al., 1977), both isozymes are protected from inhibition by propiolaldehyde by incubation with NAD^+

V. Concluding Remarks

ALDHs are a group of structurally related proteins. The majority of ALDHs facilitate the oxidation of aldehyde substrates to their corresponding carboxylic acids. Some ALDH isozymes exhibit esterase activity and functions...
unrelated to catalytic activity. In so doing, ALDH isozymes play diverse but physiologically and toxicologically critical roles. Increased or suppressed ALDH activity has been implicated in a variety of diseases, including cancer. Therefore, the application of pharmacological inhibitors or activators of ALDHs represents a rational approach for the treatment of these pathological conditions. Of the 19 known human ALDH enzymes, only a few of them have been characterized biochemically, specifically ALDH1A1, ALDH1B1, ALDH2, ALDH3A1, ALDH3B1, and ALDH7A1. Although these ALDH isozymes exhibit distinct substrate specificity, they also show an overlapping spectrum for substrates, making it difficult to precisely delineate isozyme-specific effects. Only three ALDH isozymes, ALDH1A1, ALDH2, and ALDH3A1, have been studied for vulnerability to pharmacological inhibition. No antagonists have been developed that inhibit each ALDH isozyme without affecting the others. This lack of selectivity of available antagonists for specific ALDH isozymes has not prevented clinical usage. Under these circumstances, their effects on non-ALDH enzymes limit their therapeutic utility. Nevertheless, the absence of selective pharmacological tools prevents verification of the putative roles of the ALDH protein in Figs. 2 and 4.

Acknowledgments
This work was supported by the National Institutes of Health National Eye Institute [Grants EY017963, EY11490 (both to V.V.)]; and the National Institutes of Health National Institute on Alcohol Abuse and Alcoholism [Grants R21-AA017754 (to V.V.), R37-AA00930 (to D.R.P.), AA018123, AA19746 (to T.D.H.)]. We thank Dr. Philip Reigan for his help with molecular modeling and visualization of the ALDH protein in Figs. 2 and 4.

Authorship Contributions
Wrote or contributed to the writing of the manuscript: Koppaka, Thompson, Chen, Ellermann, Nicolaou, Juvonen, Petersen, Deitrich, Hurley, and Vasiliou.

References
Badawy AA and Morgan CJ (2007) Tryptophan metabolites as potent inhibitors of


Kim KJ, Pearl PL, Jensen K, Sneed OC, Jakobs C, and Gibson KM (2011a) Nucleoside semialdehydes: biochemical-molecular-clinical dis-


Lehneke OE, Petersen DR, Collins AC, and Anderson AD (1977) Preferential inhibi-


Marchionna H and Tottman O (1983) Studies in vitro on the inactivation of mitochondrial rat-liver aldehyde dehydrogenase by the alcohol-sensitizing compounds cyano-


Meadows MR, NE (2007) Purine nucleosides (Kudzu) as mild anxiolytics and aldehyde-


ALDEHYDE DEHYDROGENASE INHIBITORS


